What do a pregnant woman, a child bitten by a rabid dog, and a newborn exposed to hepatitis B have in common?
Their lives may depend on a medicine that most people have never heard of, and that the world is quietly running short of.
The latest The Lancet Haematology article shines a light on the fragile global supply of human hyperimmune immunoglobulins. These are not niche products. They are essential, time-critical medicines that protect mothers, save children, and strengthen our preparedness for infectious disease outbreaks.
The question is no longer whether shortages will happen. It is whether we will act before patients pay the price.
If you are a policy maker, plasma industry leader, blood service professional, clinician, researcher, or advocate, I invite you to read this article and share your perspective. Solving this challenge will require all of us.
Sincere thanks to the team for this important collaboration, and especially to Professor Thierry Burnouf Jay Epstein Ellen van der Schoot Yuyun Maryuningsih for their vision, guidance, and unwavering commitment to improving global access to these life-saving therapies.
What should be our next priority to secure equitable access to these essential medicines? I look forward to your thoughts.
Here is the link to access:https://lnkd.in/gK6n–bq
Resharing the wise words of our partner from Cameroon, Fonkou Steve.